These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 24954063)

  • 1. Effects of dopamine D2/D3 blockade on human sensory and sensorimotor gating in initially antipsychotic-naive, first-episode schizophrenia patients.
    Düring S; Glenthøj BY; Andersen GS; Oranje B
    Neuropsychopharmacology; 2014 Dec; 39(13):3000-8. PubMed ID: 24954063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Blocking D2/D3 Receptors on Mismatch Negativity and P3a Amplitude of Initially Antipsychotic Naïve, First Episode Schizophrenia Patients.
    Düring S; Glenthøj BY; Oranje B
    Int J Neuropsychopharmacol; 2015 Oct; 19(3):pyv109. PubMed ID: 26453696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensorimotor gating and habituation of the startle response in schizophrenic patients randomly treated with amisulpride or olanzapine.
    Quednow BB; Wagner M; Westheide J; Beckmann K; Bliesener N; Maier W; Kühn KU
    Biol Psychiatry; 2006 Mar; 59(6):536-45. PubMed ID: 16139819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of aripiprazole, risperidone, and amisulpride on sensory and sensorimotor gating in healthy 'low and high gating' humans and relation to psychometry.
    Csomor PA; Preller KH; Geyer MA; Studerus E; Huber T; Vollenweider FX
    Neuropsychopharmacology; 2014 Sep; 39(10):2485-96. PubMed ID: 24801767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frontal fasciculi and psychotic symptoms in antipsychotic-naive patients with schizophrenia before and after 6 weeks of selective dopamine D2/3 receptor blockade.
    Ebdrup BH; Raghava JM; Nielsen MØ; Rostrup E; Glenthøj B
    J Psychiatry Neurosci; 2016 Mar; 41(2):133-41. PubMed ID: 26599135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Haloperidol differentially modulates prepulse inhibition and p50 suppression in healthy humans stratified for low and high gating levels.
    Csomor PA; Stadler RR; Feldon J; Yee BK; Geyer MA; Vollenweider FX
    Neuropsychopharmacology; 2008 Feb; 33(3):497-512. PubMed ID: 17460616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensorimotor gating and habituation in antipsychotic-naive, first-episode schizophrenia patients before and after 6 months' treatment with quetiapine.
    Aggernaes B; Glenthoj BY; Ebdrup BH; Rasmussen H; Lublin H; Oranje B
    Int J Neuropsychopharmacol; 2010 Nov; 13(10):1383-95. PubMed ID: 20633319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impaired sensorimotor gating of the acoustic startle response in the prodrome of schizophrenia.
    Quednow BB; Frommann I; Berning J; Kühn KU; Maier W; Wagner M
    Biol Psychiatry; 2008 Nov; 64(9):766-73. PubMed ID: 18514166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repeated but not acute treatment with ∆⁹-tetrahydrocannabinol disrupts prepulse inhibition of the acoustic startle: reversal by the dopamine D₂/₃ receptor antagonist haloperidol.
    Tournier BB; Ginovart N
    Eur Neuropsychopharmacol; 2014 Aug; 24(8):1415-23. PubMed ID: 24846537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology -- a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group.
    Wetzel H; Gründer G; Hillert A; Philipp M; Gattaz WF; Sauer H; Adler G; Schröder J; Rein W; Benkert O
    Psychopharmacology (Berl); 1998 Jun; 137(3):223-32. PubMed ID: 9682999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P50 suppression and its neural generators in antipsychotic-naive first-episode schizophrenia before and after 6 months of quetiapine treatment.
    Oranje B; Aggernaes B; Rasmussen H; Ebdrup BH; Glenthøj BY
    Schizophr Bull; 2013 Mar; 39(2):472-80. PubMed ID: 22241164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensory gating in schizophrenia: P50 and N100 gating in antipsychotic-free subjects at risk, first-episode, and chronic patients.
    Brockhaus-Dumke A; Schultze-Lutter F; Mueller R; Tendolkar I; Bechdolf A; Pukrop R; Klosterkoetter J; Ruhrmann S
    Biol Psychiatry; 2008 Sep; 64(5):376-84. PubMed ID: 18395700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dorsal striatum D1-expressing neurons are involved with sensorimotor gating on prepulse inhibition test.
    Rodrigues S; Salum C; Ferreira TL
    J Psychopharmacol; 2017 Apr; 31(4):505-513. PubMed ID: 28114835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroleptic effects on P50 sensory gating in patients with first-episode never-medicated schizophrenia.
    Hong X; Chan RC; Zhuang X; Jiang T; Wan X; Wang J; Xiao B; Zhou H; Jiang L; Weng B
    Schizophr Res; 2009 Mar; 108(1-3):151-7. PubMed ID: 19106034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensory-gating deficit of the N100 mid-latency auditory evoked potential in medicated schizophrenia patients.
    Boutros NN; Brockhaus-Dumke A; Gjini K; Vedeniapin A; Elfakhani M; Burroughs S; Keshavan M
    Schizophr Res; 2009 Sep; 113(2-3):339-46. PubMed ID: 19524407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects of acute serotonin and dopamine depletion on prepulse inhibition and p50 suppression measures of sensorimotor and sensory gating in humans.
    Mann C; Croft RJ; Scholes KE; Dunne A; O'Neill BV; Leung S; Copolov D; Phan KL; Nathan PJ
    Neuropsychopharmacology; 2008 Jun; 33(7):1653-66. PubMed ID: 17895917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Striatal D(2/3) Binding Potential Values in Drug-Naïve First-Episode Schizophrenia Patients Correlate With Treatment Outcome.
    Wulff S; Pinborg LH; Svarer C; Jensen LT; Nielsen MØ; Allerup P; Bak N; Rasmussen H; Frandsen E; Rostrup E; Glenthøj BY
    Schizophr Bull; 2015 Sep; 41(5):1143-52. PubMed ID: 25698711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensorimotor gating is associated with CHRNA3 polymorphisms in schizophrenia and healthy volunteers.
    Petrovsky N; Quednow BB; Ettinger U; Schmechtig A; Mössner R; Collier DA; Kühn KU; Maier W; Wagner M; Kumari V
    Neuropsychopharmacology; 2010 Jun; 35(7):1429-39. PubMed ID: 20393456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of methylphenidate on sensory and sensorimotor gating of initially psychostimulant-naïve adult ADHD patients.
    Sommer JL; Low AM; Jepsen JRM; Fagerlund B; Vangkilde S; Habekost T; Glenthøj B; Oranje B
    Eur Neuropsychopharmacol; 2021 May; 46():83-92. PubMed ID: 33663902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity.
    Schoemaker H; Claustre Y; Fage D; Rouquier L; Chergui K; Curet O; Oblin A; Gonon F; Carter C; Benavides J; Scatton B
    J Pharmacol Exp Ther; 1997 Jan; 280(1):83-97. PubMed ID: 8996185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.